Source
Cardiology Advisor
Tafamidis treatment was associated with a significant reduction in the risk of ischemic stroke in patients with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) and atrial fibrillation who were receiving direct oral anticoagulants.
This is according to a study by researchers at the Mayo Clinic in Phoenix, Arizona, and Boston Medical Center in Brighton, Massachusetts, the results of which will be presented at the American College of Cardiology 2026 Annual Scientific Session.
“These findings suggest tafamidis may protect this population beyond transthyretin stabilization alone,” the authors of the study said.
News Url